Authors

  1. Given, Barbara A. PhD, RN, FAAN
  2. Given, Charles W. PhD

Article Content

We see on every street corner, every hallway, and every stoplight, individuals using their smartphones. Yet in healthcare, we have been slow to adopt personalized communication with our patients. The research, however, shows that the connection a patient has with clinicians can improve health status outcomes through active participation, which we often refer to as engagement when patients adhere to a medical regimen, report symptoms, and carry out self-care.1,2 It is time that nurses and other clinicians consider how we can enhance communication connections with cancer patients so that we can identify toxic adverse effects, symptoms, and poor levels of adherence and introduce in more timely manners the interventions that address areas such as symptom severity during active treatment.

 

Numerous intervention studies have documented how patients benefit from symptom management. Basch and colleagues,3 Given and colleagues,4,5 Di Maio and colleagues,6 and Sikorskii and colleagues7 have reported on the value of patient-reported symptoms. Interventions responding to patient-reported symptoms have shown improvement in symptom severity, symptom interference, and effects on physical function and emotional health. The effect of unmanaged symptoms on health system usage is widely acknowledged. Common Terminology Criteria for Adverse Events reports that the Common Terminology Criteria for Adverse Events may miss up to 50% of the adverse effects that cancer patients report.3

 

We have to wonder why better connection and communication with the thousands of patients who have unmanaged symptoms and adverse effects including pain is not an important identified research priority in reports such as the Cancer Moonshot Blue Ribbon Panel Report.8 Moreover, how much additional benefit might we be able to attribute to our treatments' effectiveness if we managed patient symptoms more effectively? Three decades ago, we began investigating symptom status and management, and today, as then, patients come to studies when in active treatment with an average of 5 to 6 unmanaged symptoms. Why have we made so little progress in the management of symptoms for which we have evidence?9

 

Symptoms are disabling and can interfere with treatment, but often, patients experience these alone in their own home, without clinician communication for self-care management. Early detection of symptom severity could alert the clinicians to changing patient conditions and results in early action to prevent medication interruptions or complications. This could prevent urgent care, emergency visits, and hospitalization for unmanaged problems (eg, pain, vomiting, diarrhea, dehydration, and infection). There continues to be challenges and reservations in use of telehealth and patient communication of symptoms. Patients often indicate that a history of the pattern of symptom experience between visits is not ascertained. Oncology providers see patient-reported symptoms as less valuable and seem reluctant to make management decisions based on patient-reported symptom data. If patient reports were valued by clinicians, they would be more directly assessed and monitored so that supportive decisions could be made. Clinicians still focus on laboratory tests drawn at weekly or biweekly intervals and see patients at their routine clinic visits and use this laboratory information to guide and adjust treatment. Two-way communication, being connected, to allow real-time communication about unmanaged symptoms has to be considered if we are to improve the cancer experience for the patients.

 

Even though electronic medical record systems are widely used, we have not seen rapid movement toward having patients add their symptom status to these electronic medical record systems or even to report their symptoms using the number of symptom monitoring applications that exist. National Cancer Institute, American Society of Clinical Oncology, and numerous pharmaceutical companies have free symptom-reporting apps specific to cancer treatment. Some have the capacity to send the results on to the healthcare system. When queried about lack of use, healthcare professionals indicate that clinics are too busy to review symptom reports from patients, whereas others speak to the legal liability. This refusal to accept information from the patient is, we argue, a barrier to better patient connections and causes unnecessary patient suffering and may contribute to treatment alterations with subsequent effect on treatment outcomes. Overall, this attenuates the quality of comprehensive cancer care that patients receive.

 

How are we going to integrate effective intervention into cancer treatment to actively and directly communicate and engage patients in their symptom management at home? Why, given how we use smartphones for managing so many other parts of lives, are we unable to extend these lines of care between cancer centers and the patients they are treating?10

 

This will change overtime brought on by the demands of patients such as the millennials who will insist on being connected. Until that time, because nurses are responsible for much of the symptom monitoring and management, we can take the leadership to help set up systems and processes as standards of good care to help patients be connected during their active cancer treatment. If more research is needed to document the effectiveness, nurse researchers can do that research. Having patients connected to their professional team during active treatment moves toward care that would be truly more patient centered care, showing that we care about the patient's cancer experience.

 

References

 

1. Castro EM, Van Regenmortel T, Vanhaecht K, Sermeus W, Van Hecke A. Patient empowerment, patient participation and patient-centeredness in hospital care: a concept analysis based on a literature review. Patient Educ Couns. 2016;99(12):1923-1939. [Context Link]

 

2. Zachariae R, Pedersen CG, Jensen AB, Ehrnrooth E, Rossen PB, von der Maase H. Association of perceived physician communication style with patient satisfaction, distress, cancer-related self-efficacy, and perceived control over the disease. Br J Cancer. 2003;88(5):658-665. [Context Link]

 

3. Basch E, Rogak LJ, Dueck AC. Methods for implementing and reporting patient-reported outcome (PRO) measures of symptomatic adverse events in cancer clinical trials. Clin Ther. 2016;38(4):821-830. [Context Link]

 

4. Given B, Given CW, McCorkle R, et al. Pain and fatigue management: results of a nursing randomized clinical trial. Oncol Nurs Forum. 2002;29:949-956. [Context Link]

 

5. Given C, Given B, Rahbar M, et al. Effect of a cognitive behavioral intervention on reducing symptom severity during chemotherapy. J Clin Oncol. 2004;22(3):507-516. [Context Link]

 

6. Di Maio M, Gallo C, Leighl NB, et al. Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trials. J Clin Oncol. 2015;33:910-915. [Context Link]

 

7. Sikorskii A, Given CW, Given B, et al. Symptom management for cancer patients: a trial comparing two multimodal interventions. J Pain Symptom Manage. 2007;34:253-264. [Context Link]

 

8. Jacks T, Jaffee E, Singer D. Cancer Moonshot Blue Ribbon Panel report. Washinton DC: National Cancer Advisory Board; 2016. [Context Link]

 

9. Given B, Given CW. National Institutes of Health grant 1R01CA162401-01A1, Improving adherence to oral cancer agents and self-care of symptoms using an IVR. 2013-2017. [Context Link]

 

10. Abdullah M, Theobald DE, Butler D, et al. Access to communication technologies in a sample of cancer patients: an urban and rural survey. BMC Cancer. 2005;5:18. [Context Link]

Bibliography

 

Basch E, Jia X, Heller G, et al. Adverse symptom event reporting by patients vs clinicians: relationships with clinical outcomes. J Natl Cancer Inst. 2009;101(23):1624-1632.

 

Basch E, Wood WA, Schrag D, et al. Feasibility and clinical impact of sharing patient-reported symptom toxicities and performance status with clinical investigators during a phase 2 cancer treatment trial. Clin Trials. 2015;13(3):331-337.

 

Falchook AD, Tracton G, Stravers L, et al. Use of mobile device technology to continuously collect patient-reported symptoms during radiation therapy for head and neck cancer: a prospective feasibility study. Adv Radiat Oncol. 2016;1:115-121.

 

Yates P, Aranda S, Hargraves M, et al. Randomized controlled trial of an educational intervention for managing fatigue in women receiving adjuvant chemotherapy for early-stage breast cancer. J Clin Oncol. 2005;23:6027-6036.